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1. CD40 regulates BM immunological tolerance following total body irradiation (TBI) and 
transplantation (BMT). 




Allogeneic bone marrow transplantation remains the only therapeutic option for a wide range 
of hematological malignancies despite the risk of possible adverse, immune-related events, 
such as infection and acute graft-versus-host disease (aGVHD). aGVHD is characterized by 
T-cell activation, defective B-cell development and osteoblastic niche destruction in bone 
marrow (BM) among other issues. Transplant conditioning regimens cause excessive 
inflammatory cytokines production and impaired regulatory T-cell control of aberrant T-cell 
activation. Here, we show that mesenchymal cells (MSCs) upregulated CD40 upon 
irradiation at the expense of mesenchymal markers, and that CD40 endows MSC of 
regulatory function on Treg homeostasis and fitness. Transplantation of wild type 
hematopoietic cells into a CD40-null recipient reduces Treg numbers allowing persistent T-
cell activation and pro-inflammatory cytokines production causing, impaired B-
lymphopoiesis. These evidences find correlation in aGVHD patients showing the loss of 
CD40+ BM-MSCs along with reduction in cells of the B-lineage. Modeling aGVHD in mice 
we show that the elimination of CD40+ BM-MSCs relies on their higher expression of MHC-
I molecules. Indeed, aGVHD mice compared to MHC-matched controls showed the loss of 
MHC-I + radio-resistant host BM-MSCs. Our data point to CD40+ MHC-I+BM-MSCs as a 
key regulator of BM tolerogenic niches.  
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Allogeneic bone marrow transplantation (BMT) remains the only therapeutic option for a 
wide range of hematological malignancies. However, it carries a significant risk of morbidity 
and mortality, which are mostly linked to adverse, immune-related events, such as infection 
and acute graft-versus-host disease (aGVHD). Thus, a better understanding of the 
mechanisms underlying immune regulation during bone marrow (BM) transplantation would 
significantly expand its application and potential benefits. 
The BM has the features of an immune-privileged organ. This condition is granted by its 
peculiar enrichment in Foxp3+ regulatory T-cells (Tregs), which represent up to 30-40% of 
the total CD4 T-cell population, exceeding the fraction of Tregs in other lymphoid organs by 
3- to 4-fold. In the BM, Tregs populate hematopoietic stem cell (HSC) niches where they 
protect endogenous HSCs from excessive inflammation and, during BMT, enable 
transplanted allogeneic HSCs to avoid rejection 1 2.  Indeed, an excess of inflammatory 
cytokines, such as interferon (IFN) or tumor necrosis factor (TNF), can induce HSC 
dysfunction and hamper HSC differentiation into mature myelo-lymphoid lineages. After 
BMT, B-cells are particularly sensitive to the inflammatory conditions within the 
microenvironment and largely depend on the Tregs for proper reconstitution. In fact, B-cell 
lymphopoiesis depends on interleukin (IL)-7, which is defective in Treg-depleted mice 3. 
Furthermore, Treg depletion unleashes the production of granulocyte-macrophage colony-
stimulating factor (GM-CSF), IL-6, and TNF, which promote granulopoiesis at the expense 
of B lymphopoiesis 4. Also IFN-γ negatively affects B-cell lymphopoiesis 4,5, suggesting that 
BM microenvironmental inflammatory state largely depend on Treg surveillance.  
Tregs regulation has been largely studies in different tissues, but less so in the BM 
microenvironment. In the periphery, Treg development depends on transforming growth 
factor (TGF)-β and IL-2, while in the thymus IL-2 is dispensable because other coexisting 
cytokines can act on the IL-2Rβ chain 6. Further, the cluster of differentiation (CD)40/CD40 
ligand (L) axis also contributes to the peripheral Treg pool 7.  
Bone marrow mesenchymal stroma cells (BM-MSCs) nurse HSCs and progenitor cells 
through the stages of quiescence/self-renewal and differentiation 8. In addition to supporting 
HSC, BM-MSCs also exert immunoregulatory functions: they can inhibit the proliferation of 
T, B and natural killer (NK) lymphocytes 9 and promote the conversion of Teff to Treg, in 
vitro. On this line, in vivo administration of BM-MSCs has beneficial effects in the treatment 
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of aGVHD 10. Beside the production of regulatory metabolic enzymes like indoleamine-2,3-
dioxygenase (IDO) 11, the repertoire of co-stimulatory and/or co-inhibitory molecules 
harnessing BM-MSCs for immune regulation, including the role of CD40, is largely 
unknown. The lack of CD40 expression in normal BM and its upregulation on BM-MSCs of 
patients affected by splenic marginal zone lymphoma 12, suggest that BM-MSC can gain 
immunoregulatory properties in response to microenvironment perturbation.  
In this study, we evaluated the role of CD40 on BM-MSCs in sustaining a BM 
tolerogenic state in the context of pro-inflammatory signals preventing unwanted T-cell 
activation that could negatively impact on hematopoiesis.  
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Patients. This study included bone marrow biopsies from 12 adult acute leukemia patients 
undergoing allo-HSCT at the Charité university hospital. 
The patients’ clinical characteristics and GVHD prophylaxis are summarized in Table 1. 
The study was approved by the Charité-Berlin local ethics committee. Patients gave informed 
consent. The study was conducted in accordance with the Declaration of Helsinki" 
 
Mice. BALB/cAnNCrl and C57BL/6 mice were purchased from Charles River Laboratories 
(Calco, Italy). Tnfrsf5 (Cd40)-KO mice (on a BALB/c background) were already available in 
our lab, while those on a C57BL/6 background were obtained from Dr. Dellabona Paolo (San 
Raffaele Hospital, Milan, Italy) and Prof. Bronte Vincenzo (University of Verona, Verona, 
Italy). CxB6F1 (Cd40)-KO mice were obtained by crossing the Cd40-KO on the BALB/c 
background with those on the C57BL/6 background. All experiments involving animals 
described in this study were approved by the Ministry of Health (authorization number n. 
601/2019-PR).  
 
BMT and aGVHD mouse experiments. Canonical BMT experiments were performed by 
transplanting 2 × 105 lin- cells into lethally irradiated WT and Cd40-KO mice as previously 
described 13. MHC-mismatched BMT was performed transplanting lethally irradiated 
BALB/c mice with 2 × 106 T-cell-depleted BM cells from C57BL/6 mice in the presence or 
absence of Teff cells (2 × 105) from the same donors. T-cell-depleted BM was obtained by 
flushing the BM cells from donors and incubating them with α-CD5 (Ly-1) microbeads from 
Miltenyi. Mice were assessed daily using a GVHD scoring system that measures items 
related to the known clinical signs of GVHD, including weight loss, posture, activity, fur 
texture, skin integrity, and diarrhea.  
 
Flow cytometry. The composition of the B-cell compartment in the BM and spleens of BM 
chimeras was analyzed as previously described 14. Notably, B-cell development in the BM 
has been classified into sequential subsets designated Fractions A, B, C, C’, D, E, and F as 
originally described by Hardy et al. 15.  
Surface staining was performed in phosphate-buffered saline (PBS) supplemented with 
2% fetal bovine serum (FBS) for 30 min on ice. Foxp3 intracellular staining was performed 
according to the manufacturer’s instructions (eBioscience). Before IFN-γ staining, the cells 
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were stimulated in vitro for 4 h at 37°C with Cell Stimulation Cocktail plus protein transport 
inhibitors (eBioscience).  
All antibodies are listed in Supplemental Table 2. Flow cytometry data were acquired on 
a LSRFortessa (Becton Dickinson) and analyzed with FlowJo software (version 8.8.6, Tree 
Star Inc.). 
 
Isolation and culture of murine BM-MSCs. Murine BM-MSC cultures were obtained from 
the trabecular fraction of femurs and tibias of WT and CD40-KO mice. Briefly, the cellular 
fraction of the femurs and tibias was washed out and the compact bone was incubated with 
collagenase I (1 mg/ml) for 1 h at 37°C. After enzyme digestion, the bone suspension was 
passed through a 70-mm filter mesh to remove any bone spicules and large tissues. Cells 
were seeded in complete medium at a density of 25 × 106 cells/ml. Floating cells were 
removed every 3-4 days. Adherent cells were phenotypically characterized using the 
following antibodies: CD31, CD45, CD34, Ter119, CD44, Sca-1, and CD117. In vitro and in 
vivo experiments involving murine BM-MSCs were performed using cells between the 2nd 
and 5th passages.  
 
Statistical analysis. In transplantation analysis an ordinary one-way ANOVA was used, 
while for all the other comparisons the Unpaired t-test was used. Error bars in all graphs 
represent mean and standard deviation. All statistical analyses were performed with Prism 6 
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Lethal irradiation perturbs BM T-cell homeostasis and promotes the expression of CD40 in 
stromal cells. 
We previously shown that CD40 expression characterizes stromal cells of patients who had 
the BM infiltrated by splenic marginal zone lymphoma. In these patient CD40 promotes a 
pro-inflammatory loop with mast cells, which sustain lymphoma cell growth 12.  We analyzed 
the BM of mice developing autoimmunity and characterized for the expansion of IFN-γ + 
Teff 16. Stromal cells of these mice expressed CD40, compared to untreated mice (Online 
Supplementary Figure 1A). These data suggested that the presence of inflammatory cytokines 
such as IFN-γ could be relevant in increasing CD40 expression on BM-MSCs.  Therefore we 
performed an in vitro analysis using primary human BM-MSCs and found that CD40 
expression is induced by IFN-γ paralleling the induction of IDO1, a well know immune-
regulatory molecules (Online Supplementary Figure 1B). These data suggested that MSC-
derived CD40 could be relevant in the BM microenvironment when this microenvironment is 
perturbed toward the production of inflammatory cytokines.  
Total body irradiation (TBI) is known to affect the BM immune microenvironment firstly 
inducing cytokines and then local immunosuppression to prevent the rejection of the donor 
bone marrow 17. We evaluated whether CD40 expression, undetectable in the BM-
microenvironment in basal conditions, is induced by TBI. To this end BALB/c mice were 
lethally irradiated and sacrificed 4 or 7 days post-radiation to collect radiation-resistant BM-
MSCs 18. Both RT-PCR (Figure 1A) on ex-vivo purified BM-MSCs (Online Supplementary 
Fig. 1C) and immunohistochemistry (IHC) (Figure 1B) showed that CD40 was overexpressed 
on total BM-MSCs at day 7 post-radiation compared to basal and day 4. The analysis of T-
cell compartment showed the expansion of CD4+ cells upon irradiation both after 4 days and 
7 days compared to non-irradiated mice (Figure 1C). Among CD4+ cells, we noticed that 
Teffs (CD4+Foxp3-) were increased in frequency compared to Tregs (CD4+Foxp3+) (Figure 
1D). Moreover, the Teffs were activated to release TNF and IFNγ (Figure 1E), which, tested 
in vitro, were able to induce strong CD40 up-regulation in ex-vivo isolated and in vitro-
expanded BM-MSCs (Figure 1F) in comparison to other stimuli also released in the BM of 
conditioned mice (i.e., G-CSF, GM-CSF+IL-6, and IL-17) 19 (Online Supplementary Figure 
2A). 
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To better characterize the BM-MSCs population expressing CD40 after TBI, we performed a 
multiparametric flow cytometry analysis. To define BM-MSCs we checked positivity for 
known surface MSC markers (CD44, CD29, Sca-1) and negativity for the lineage markers 
CD45, Ter119, CD34, CD117 and CD31. To our analysis we also added the CD73 marker, as 
it was recently attributed to radio-resistant and clonogenically-active BM-MSC 20. Our 
analysis showed that within the gate of CD29+CD44+CD45-Ter119-CD31-CD34-CD117- 
cells, lethal irradiation increased the frequency of Sca-1+ cells (Figure 1G). However, within 
both Sca-1+ and Sca-1- cells we found an increased frequency of CD73+ cells (Figure 1H). 
Paralleling CD73 we found that the frequency of CD40+ BM-MSCs was strongly increased 
after irradiation (Figure 1H). This suggests that CD40, as CD73, could be specifically 
induced and associated to radio-resistant BM-MSCs that could be either Sca-1+ or Sca-1-. 
Looking at the frequency of BM-MSCs co-expressing CD40 and CD73 within the gate of 
total BM-MSCs (CD29+CD44+CD45-Ter119-CD31- CD34-CD117-) we found an increased 
frequency of double positive CD40+CD73- and CD40+CD73+ BM-MSCs upon irradiation 
(Figure 1I). The representative gating strategy is shown in Figure 1J.  
To test whether the gain of immune regulatory features in BM-MSCs occured at the expense 
of their differentiation program toward osteo-and adipo- lineages, we performed RT-PCR 
analyses on TNF and IFN-γ  stimulated cells. Osteoblast and adipocytes differentiation 
markers such as osterix, osteonectin, osteopontin, bglap, PPARg, were all down-modulated 
by TNF; osterix, Runx2, Sparc and Spp1 but not Bglap and PPARg were down-modulated by 
IFN-γ (Online Supplementary 2B). The combination of TNF and IFN-γ was additive in 
decreasing the expression of Spp1 (Online Supplementary 2B). As control, the same MSCs 
showed increased CD40 expression, suggesting an inverse relationship between the 
expression of immune and differentiation programs.  
 
Altered B-cell lymphopoiesis in the BM is a characteristic of Cd40-KO recipient chimeric 
mice. To study the regulatory role of CD40 on BM-MSCs in vivo, we set up bone marrow 
transplant (BMT) experiments in which recipient mice (either Cd40-KO or WT, all CD90.2) 
were lethally irradiated and transplanted with HSCs from congeneic CD90.1 WT donors. 
Twenty-one days post-BMT we performed FACS on peripheral blood (PB), BM, and spleens 
of recipient mice. Compared to WT, Cd40-KO recipients showed a prominent decrease in the 
frequency of PB B-cells and, to a lesser extent, of T-cells, but also an increased frequency of 
CD11b+ myeloid cells (Fig. 2A, Online Supplementary 3A). In line with our PB analysis, we 
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observed a reduction of lymphoid cells in the BM of Cd40-KO recipients despite normal 
myelopoietic (CD11b cells) development (Figure 2B). Particularly, B-cell development was 
largely defective, as shown by the reduced B220+CD43+ and almost absent B220+CD43- 
fractions (Figure 2B). B-cell development was arrested at the A and B fractions, which 
correspond to the pre-pro-B and early pro-B phases, respectively, with reduced development 
of the fraction of C’-C precursors (late pro-B and large pre-B) (Figure 2C; Online 
Supplementary 3B) 15. Intriguingly, in the spleens of Cd40-KO recipients we noted an 
increased frequency of B220+CD43+ B-cell precursors that developed into mature B-cells of 
different types, thus giving rise to extramedullary B lymphopoiesis (Figure 2 D-E). However, 
the overall frequency of B220+ cells was significantly reduced in the spleen of Cd40-KO 
recipients (Figure 2F) with a significant impairment in the CD93+ immature fraction 
(particularly affected were transitional T1 cells, Figure 2G). Nevertheless, the presence of 
mature marginal zone B-cell and follicular B-cell (Figure 2H; Supplemental Figure 3C) 
suggested a compensatory role for splenic B-cell lymphopoiesis in response to dysfunctional 
BM B-lymphopoiesis. Notably, the defective B-cell lymphopoiesis in the Cd40-KO recipient 
chimeras was not due to a systemic anti-CD40 response as CD40+ B-cells were still present 
in the spleen and PB (Online Supplementary Figure 4A). The relevance of BM-MSC-derived 
CD40 in B cell development was also suggested by the close contact between CD40+ 
mesenchymal cells and B220+ cells in vivo as detected by confocal microscopy analysis for 
B220 and CD40 on BM biopsies (Figure 2I). We functionally proved this hypothesis by 
performing a BMT experiment where WT mice were lethally irradiated and reconstituted 
with Lin- cells in the presence of either WT or Cd40-KO BM-MSCs. BM-MSCs were also 
forced to express CXCR4 to promote BM homing. The presence of WT CXCR4+ BM-MSCs 
promoted a higher frequency of B220+ cells compared to mice that did not received MSCs 
(Figure 2J) at day 14 post-BMT. On the contrary, Cd40-KO BM-MSC negatively affected B 
cell development and 33% of mice died (Figure 2J).  
 
CD40-deficiency in the BM stromal compartment creates a lymphopoietic niche unfit to 
respond under stress condition. We next tested whether the lack of stromal CD40 expression 
might negatively impact on Treg development or generate a pro-inflammatory 
microenvironment, which in turn can inhibits B-cell development.  
To this end, we analyzed BM T-cell status in WT> Cd40-KO and WT>WT chimeras, 4 
weeks after BMT. Tregs were reduced in the BM of WT> Cd40-KO chimeras compared to 
the WT>WT counterpart (Figure 3A), and IFNγ-producing Teff cells were significantly 
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increased (Figure 3B, C). To gain further insight into the behavior of Tregs in the Cd40-KO 
recipients and their relationships with B-cell development, Tregs were co-infused with donor 
lin- cells (both B/c, H-2d) into either WT or Cd40-KO F1 recipients (both CxB6, H-2b/d) 
(Online Supplementary Figure 5A). Of note, Tregs accelerated the recovery of B-cells in BM 
of WT>WT chimeras (Figure 3D), but not in Cd40-KO recipients. In line with this result, a 
reduced frequency of donor Tregs was observed in Cd40-KO compared to WT recipients 
(Figure 3E). Such reduction of donor Tregs was paralleled by decreased Foxp3 levels (Figure 
3F) and increased production of IL-17 in the CD4+Foxp3low population (Figure 3G, H) in 
Cd40-KO recipients. This phenotype suggests a possible conversion of Tregs into Th17 cells 
21. In line, transplantation of WT donor cells into Cd40-KO recipients resulted in reduced 
OX40 expression on Tregs, a known marker of fitness 22 (Online Supplementary Figure 5B). 
To try to explain this phenotype, we evaluated OX40L expression in Cd40-KO and wt BM-
MSCs. Indeed, previous data have shown that in the absence of an intact CD40/CD40L axis, 
OX40 triggering could worsen allograft rejection in cardiac transplant model, through the 
exacerbation of the Th1 and Th2 responses 23. RT-PCR analysis performed onto ex-vivo 
stimulated BM-MSCs showed that Cd40-KO BM-MSCs had higher OX40L levels than their 
WT counterparts in response to TNF (Figure 3I). In line, BM IHC for OX40L showed an 
overall increase in its expression in Cd40-KO recipient mice (Figure 3J), and confocal 
microscopy analysis revealed co-staining with the nestin marker (Online Supplementary 
Figure 5C). These data could explain the observed impairment of Tregs in favor of Teffs in 
the WT>Cd40-KO chimeras. In fact, the increased OX40L stimulation was previously shown 
to promote the conversion of Tregs to Th17 24. This is compatible with our earlier findings of 
increased production of IL-17 in Foxp3low cells of Cd40-KO recipient mice. Conversely, 
upon OX40L stimulation, Teff cells increase proliferation and acquire memory functions 25,26.  
Overall, these data suggest that in the absence of CD40, BM-MSCs are unable to regulate 
donor Treg activity. Indeed, under certain inflammatory stimuli Treg may might lose FOXP3 
expression and acquire the ability to produce Th cytokines 27. 
 
Stromal CD40 expression is downregulated during BM manifestation of acute- GVHD 
disease. Allogeneic HSC transplantation is an effective treatment for many hematologic 
diseases, but one major treatment-associated complication is aGVHD. aGVHD patients often 
show impaired B-cell immunity as well as activated donor T-cell-mediated osteoblast 
destruction 28 29. Given the striking similarity of this phenotype with our findings in the BM 
of irradiated Cd40-KO mice, we set up experiments to evaluate whether the loss of CD40 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 10, 2020. . https://doi.org/10.1101/2020.08.10.243691doi: bioRxiv preprint 
	 11	
expression on BM-MSCs could be a common feature in BM experiencing an abnormal T-cell 
activation, such as during aGVHD pathogenesis. To model GVHD, we used an experimental 
model in which major histocompatibility complex (MHC)-mismatched BM cells and 
lymphocytes isolated from C57BL/6 (H2b) donors were transplanted into BALB/c (H2d) 
recipients. 2 × 106 T-depleted donor BM (TD-BM) cells were co-infused or not (control) with 
5 × 105 donor CD4+CD25- (Teff) lymphocytes 30. As a further control, a non-MHC 
mismatched BMT was also performed using BALB/c (H2d) mice as both donor and recipient 
(Supplemental Fig. 6A). Under the allogeneic conditions, aGVHD manifested within 21 days 
as confirmed by changes in mice weight (Online Supplementary Figure 6B) and histological 
analysis of the liver, skin and lung, in accordance with a murine grading system (Online 
Supplementary Figure 6C-D) 31. FACS analysis of BM cell suspensions isolated from these 
mice revealed impaired B-cell development associated with an increased production of IFN-γ  
and TNFα by CD4 and CD8+ cells (Figure 4A).  Notably, Treg frequency was significantly 
reduced in mice with aGVHD. Similar changes in the B-cell and Treg populations were also 
detected in PB samples, where a time-dependent loss of both cell types was observed (Figure 
4B-C). These data suggest that Treg and B-cell frequencies could be used as early markers to 
identify patients who will likely develop aGVHD. 
We next analyzed CD40 expression in the BM microenvironment during aGVHD. RT-PCR 
analysis showed loss of CD40 expression in freshly isolated BM-MSCs from aGVHD but not 
control chimeras (Figure 4D). IHC of the BM specimens confirmed CD40 loss during 
aGVHD (Figure 4E) and co-immunofluorescence analysis for nestin and CD40 confirmed the 
lack of CD40 on nestin+ stromal cells from aGVHD mice (Figure 4F). Notably, the lack of 
CD40 was coupled with increased OX40L on BM-MSCs (Figure 4G), which also showed 
increased production of NOS2 and IDO-I (Figure 4H).  These data suggest that aGVHD 
development is associated with an altered immunoregulatory axis involving CD40 expression 
on BM-MSCs and Treg. The increased expression of Ido1 and Nos2 in BM-MSCs from 
aGVHD mice suggests that different mechanisms are in place to try to restore immune 
homeostasis. However, despite these mechanisms the outcome of BMT in CD40-deficient 
mice suggests that they cannot bypass the requirement for a functional CD40-CD40L axis.   
 
Loss of MHC-Ihigh MSCs in BM from aGVHD mice. To try to explain the loss of CD40+ 
BM-MSCs we evaluated the expression of MHC-I, which is necessary for allo-recognition on 
BM-MSCs from lethally irradiated and aGVHD (TD-BM B6+Teff>B/c) vs controls (TD-BM 
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B/c+Teff>B/c) mice. Lethal irradiation increased the expression of MHC-I in Sca-1- 
CD29+CD44+ BM-MSCs (Online Supplementary Figure 7). A similar trend was observed in 
Sca-1+ cells. Both Sca-1+ and Sca-1- comprised CD40+ elements (not shown). The same 
analysis performed onto aGVHD vs controls mice, at 14 days post-transplantation, revealed a 
dramatic change in term of MHC-I+ cells composition in both the Sca-1+ and Sca-1- 
fraction. Indeed, in both populations we found an almost complete loss of MHC-IhighCD40+, 
and MHChighCD40- subsets, notably leaving intact those expressing lower level of MHC-I 
(Figure 5A-C).   
 
The absence of CD40 specifically worsen the BM manifestation of aGVHD. To assess the 
relevance of CD40 in the context of aGVHD, Cd40-KO and WT mice were transplanted with 
MHC-mismatched TD-BM cells co-infused or not with donor CD4+CD25- Teff. We found 
that transplantation of Cd40-KO mice with a MHC-mismatched BM was sufficient to 
promote an excessive production of inflammatory cytokines in the BM even in the absence of 
donor Teff (Figure 6A), so much that recipient mice were sacrificed at day 14 instead of day 
21 because of their suffering conditions (at day 12, 15 % of Cd40-KO recipients were died). 
In these mice, FACS analysis of BM cells showed a significant increase in the frequency of 
CD3+ T cells indicating that the Cd40-KO microenvironment favors the proliferation and 
pro-inflammatory activation of radioresistant host T cells (but also donor T cells, when co-
infused). Indeed, we found high production of IFN-γ  and TNF by CD4-T cells along with 
decreased frequency of B220+ cells (Figure 6A). Notably, the reduced frequency of donor 
TD-BM cells in Cd40-KO compared to WT recipients (not shown), suggests that the Cd40-
KO microenvironment might favour the generation of a graft vs donor response.  
 Histological and IHC analysis showed a reduced BM cellularity and increased expression of 
OX40L on mesenchymal elements of Cd40-KO recipients (Figure 6B). Notably, the 
exacerbated inflammatory condition due to CD40 deficiency in radio-resistant cells, both in 
presence and absence of donor Teff, was restricted to the BM environment, as the histology 
of infiltrating lymphocytes in peripheral organs (liver and skin) was not different between 
WT and Cd40-KO recipients (Online Supplementary Figure 8).  
 
Association between CD40 and PAX5 loss in aGvHD patients BOM. To assess the 
relevance of our findings in human disease, we examined BM biopsies from 12 allo-HSCT 
patients, seven of which developed aGVHD (grade I-III).  Patient’s characteristics are 
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included in Supplemental Table 1.  BM Paraffin sections were stained with Ab to CD40 and 
to PAX5, an early B-cell transcription factor expressed since the early stages of B-cell 
lymphopoiesis. A blinded analysis of these cases showed that CD40 was either not expressed, 
or expressed on scattered elements with myeloid morphology, or in spindle- or stellate-
shaped stromal cells in other different cases. The mesenchymal nature of the spindle- or 
stellate-shaped cells was confirmed by double-marker immunofluorescence analysis for 
CD40 and CD146 (Figure 7A). Pax5 expression ranged from less than 1% to nearly 20% of 
the hematopoietic cellularity and positively correlated with CD40 expression on 
mesenchymal cells. B-cell frequencies were lower in cases of non-stromal or negative 
expression of CD40. The last condition characterized GVHD patients (Figure 7B and Online 
Supplementary Table 1) in full agreement with the described mouse data. The analysis of the 
expression and localization of granzyme-B in BOM from GVHD patients showed that 
patients that had a strong reduction in PAX5+ cells had granzyme B+ granules localized onto 
CD146+ BM-MSCs cells (Figure 7C), suggesting that Teff cells are actively killing BM-
MSCs.  
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The bone marrow (BM) is a peculiar lymphoid organ. Mature and memory T cells re-
locate in the BM parenchyma, which is a potential source of effector T cells 32. This could, at 
least in part, explain why the BM is the organ with the highest frequency of Treg compared 
to other secondary lymphoid organs, such as spleen and LN 33. Furthermore, the strong 
detrimental effect of uncontrolled cytokine production over HSC homeostasis and 
differentiation might explain the need of high Treg activity to keep effector T cells silent 1. 
This is particularly evident for B-cells. In fact, the initial phases of B-cell development is 
influenced by the BM immune environment. In fact an excessive IFN-γ  production 5 or 
changes in Treg composition 3 has been shown to negatively affect B-cell development.  
Here, we provide evidence that the immune regulatory activity of BM-MSCs over Treg and 
Teff, which is generally ascribed to soluble molecules (i.e. IDO, NOS-2), relies on the 
expression of CD40, a cell surface receptor belonging to the TNF-R family which function is 
critical for the antigen presenting cells activity 34. Starting from our previous finding of CD40 
up-regulation in CD146+ mesenchymal cells of SMZL patients, we show here that CD40 
expression in the BM microenvironment is induced under inflammatory conditions, such as 
those associated with lethal irradiation. Modelling BMT in mice, we show that the post-
radiation inflammatory response, guided by IFN-γ  and TNF, is sufficient to induce CD40. 
BM-MSCs and Foxp3+ Treg cells closely interact to confer immune privilege to BM 35. We 
showed that the prompt up-regulation of CD40 in radio-resistant BM-MSCs during TBI, is 
required to grant Treg functions. Accordingly, the absence of CD40 on stromal elements 
reduces Tregs in favor of Teff, possibly via conversion to Th17 cells.  
This condition was associated to defective B-cell development in Cd40-KO mice, mirroring 
the prolonged B-cell dysfunction, the increased T-cell infiltration and the disrupted BM niche 
that characterize human aGVHD 29. Indeed, BM biopsies from aGVHD patients reveal lack 
of PAX5 expression, a marker that identifies early B-cells, along with the loss of stromal 
CD40 expression.  
Mechanistically, we found that the absence of CD40 on stromal cells was associated to higher 
level of OX40L expression, a feature underestimated in BM-MSCs. Our data suggest that in 
the absence of CD40/CD40L, the OX40/OX40L axis might prevail. In line, stimulation of 
OX40 overrides cardiac allograft acceptance induced by disrupting CD40-CD40L interaction 
23. In the BM this might favor Teff proliferation at the expense of Treg, thus creating a pro-
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inflammatory environment that in case of MHC-mismatch, might favor the development of 
aGVHD.  
The loss of CD40+ BM-MSCs in aGVHD, might be due to their high MHC-I expression. 
Indeed, modeling GVHD in mice we found a time-dependent loss of MHC-I-high MSC 
subset, which comprises CD40+ cells. This finding opens two possible scenarios: the first 
one is the existence of a MHC-driven allo-recognition and therefore elimination of MHC-I+ 
BM-MSCs, and the second one is the possible down-modulation of MHC-I molecules on 
BM-MSCs, to prevent allo-recognition. BM-biopsies from aGVHD patients showing the 
disruption of osteoblasts of the BM niche 29 together with our data showing the co-
localization of granzyme-B granules with nestin+ BM-MSCs in the same aGVHD patients 
strongly support the first hypothesis.    
Furthermore, analyzing the compartment of radio-resistant BM-MSCs we show that lethal 
irradiation increases the frequency of CD40+ BM-MSCs and that a subset of these cells are 
CD73+.  Indeed, CD73 is an ectoenzyme involved in the production of adenosine, a potent 
immune suppressive molecule, also affecting Treg 36. This might explain why the loss of 
CD40+ BM-MSCs subset during GVHD results in exacerbated inflammatory response.  
Different clinical trials testing the efficacy of BM-MSCs to prevent or treat GVHD are 
running 37. Most of them utilize allo-MSCs from third-party donors. Results from these trials 
show no collateral side effects and a good overall response rate in chronic GVHD patients. In 
aGVHD patients no significant differences have been shown among MSCs vs no MSCs 
groups, although encouraging results have been reported in one controlled clinical trial with 
40 patients in which a complete or partial response was observed in 15 and 1 patient, 
respectively.  Several clinical trials are still on going and will provide additional data to 
evaluate the efficacy of allo-MSC administration. Nevertheless, some key factors that can 
influence MSCs activity have been identified, such as the route of administration and the 
source of allo-MSCs. On this regards our data provide new insight suggesting that although 
the total MSCs population is potentially able to provide immune suppression, only the 
specific subset of BM-MSCs expressing CD40 could be the most effective for the generation 
of BM tolerance. However, their tolerogenic effect could be reduced because of their high 
expression of MHC-I molecules, which may lead to their elimination.  
 
Finally, the study shows that the gaining of regulatory functions along with CD40 
upregulation, in MSCs is associated with the down-regulation of their speciation markers 
(Bglap, Osterix, Osteopontin) in favor of immune regulatory feauture. This is either 
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explained by a more undifferentiated/progenitor subset of BM-MSCs exerting these 
functions, or by a switch from an architectural/supportive hematopoietic niche function of 
BM-MSCs to an immunoregulatory activity when excessive inflammatory conditions are 
sensed. Additionally, here we described that high expression of CD40 is on Sca-1+, a marker 
that identifies stromal progenitors able to generate both osteogenic and stromal cells and able 
to provide a supportive environment for hematopoiesis 38. It has been reported that Sca-1-
positive cells have higher colony forming ability and show enhanced proliferation compared 
with Sca-1-negative cells 39. Overall, all these pieces of evidence support the possibility that 
the subset of BM-MSCs mostly endowed with immune regulatory function could be the 
mostly undifferentiated.  
 
In conclusion, we provide evidence that stromal CD40 expression is up-regulated in 
BM-MSCs after irradiation as a step necessary to restore T cell homeostasis during HSCT. 
CD40-deficiency in BM stromal cells skews BM T cell activation towards the persistent 
production of inflammatory molecules that, in turn, impair normal B cell development. These 
CD40-dependent changes are pathogenetically relevant in human aGVHD. Based on our 
data, CD40 appears to be a key molecule conferring tolerogenic properties to BM niches.  
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Figure 1. Expression of CD40 in the BM microenvironment. A. RT-PCR showing the  
expression of CD40 on primary BM-MSCs (not expanded in vitro) purified from BM at day 4 
and 7 post-radiation and compared to basal. B. Representative image of CD40 IHC staining 
in the femurs and tibias of WT mice harvested 7 days post-irradiation. C. FACS analysis 
showing the frequency of CD4+ and CD8 T-cells in lethally irradiated (not reconstituted) 
mice (n = 5 per group). **p < 0.005, ***p < 0.001, compared by unpaired t test. D. 
Frequency of Teffs (CD25-Foxp3-) and Tregs (CD25+Foxp3+) in irradiated mice (CD4 gate) 
(n = 5 per group). **p < 0.005, ***p < 0.001, compared by unpaired t test. E. FACS analysis 
showing the frequency of Teff producing IFNγ and TNF (CD4+Foxp3- gate) (n = 5 per 
group). **p < 0.005, ***p < 0.001, compared by unpaired t test. F. Real-time PCR analysis 
for Cd40 performed on total RNA isolated from in vitro expanded BM-MSCs stimulated 24 h 
with 10 ng/ml IFNγ and TNF or their combination (n = 5 per group). **p < 0.005, ***p < 
0.001, compared by unpaired t test. G. Cumulative FACS analysis showing the frequency of 
Sca-1+ and Sca-1- BM-MSCs (CD29+CD44+CD45-Ter119-CD31-CD117-CD34- gate) in 
irradiated mice. H. Cumulative FACS analysis showing the frequency of CD73+ and CD40+ 
BM-MSCs within the Sca-1+ and Sca-1- gate. I. Cumulative FACS analysis showing the 
frequency of CD40+CD73-, CD40+CD73+ and CD40-CD73+ BM-MSCs in irradiated 
(RAD) vs non-irradiated mice (CTRL). N=8 for controls and n=10 for irradiated mice; **p < 
0.005, ***p < 0.001, ****p < 0.0001, multiple comparisons using a one-way ANOVA. J. 
Representative gating strategy for CD73 positive, CD40 positive and CD40/CD73 double 
positive MSCs is shown. 
 
Figure 2. Analysis of B-cell development in WT>WT and WT>Cd40-KO BM chimeras. 
A Cumulative data for the PB FACS analysis showing the frequencies of B220+, CD3+, 
CD11b+ cells as well as the B220/CD3 ratio in the PB of WT>Cd40-KO compared to 
WT>WT BM chimeras. Representative plots and gating strategy are shown in Supplemental 
Figure 2a B. Cumulative data for FACS analysis of the BM showing the overall decrease in 
B220+CD43+ and B220+CD43- B-cell subsets in Cd40-KO recipients along with an increase 
in the frequency of CD11b+ myeloid cells *p<0.05  C. Cumulative data showing the 
frequency of pre-pro-B and early pro-B precursors (A and B fractions), and of late pro-B and 
large pre-B precursors  (C’-C) in chimeric mice; D. Cumulative data showing the frequency 
of B220+CD43+ B-cell precursors in the spleens of Cd40-KO recipient mice (n = 6 per 
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group). E. Representative dot plots showing that B220+CD43+ cells are almost absent in the 
spleen of WT but not Cd40-KO recipients. F. Frequency of B220+ B-cells is lower in the 
spleen of chimeric mice than in WT mice. G. Frequency of B220+CD93+ and B220+CD93- 
B-cells in the spleen of chimeric mice. Splenic immature B220+CD93+ B-cell were divided 
into transitional T1, T2, and T3 cells based on their expression of CD23 and IgM (T1 = IgM 
+ CD23-, T2 = IgM + CD23+, T3 = IgMlowCD23+). H. Frequency of MZB and FoB within 
the gate of B220+CD93- cells is also highlighted. The relative gating strategy is shown in 
Supplemental Figure 2 *p < 0.05, compared using Student’s t test for all analyses. I Confocal 
microscopy analysis for CD40 (green) and B220 (red) expression showing the close contact 
between B220+ and CD40+elements in WT>WT BM chimeras. J. Dot plots showing B cell 
reconstitution in WT mice transplanted with Lin- cells co-infused with WT or Cd40-KO BM-
MSCs transduced or not with CXCR4 (n=3/group).  
  
Figure 3. Characterization of T-cell status in the Cd40-KO recipient BM chimeras. A. 
Treg frequency in the BM of WT>WT and WT>Cd40-KO BM chimeras (n = 6 per group). 
***p < 0.001, compared using Student’s t test. B. Cumulative data and C. representative dot 
gating strategy showing the production of IFNγ by CD4+Foxp3- Teffs s in the BM of 
WT>WT and WT>Cd40-KO BM chimeras (n = 6 per group). *p < 0.05, compared by 
Student’s t test. D. Frequency of B220+ cells in the WT>WT and WT>Cd40-KO BM 
chimeras after lethally irradiating CxB6F1 WT or Cd40-KO mice with lin- cells and spleen-
derived Tregs from donor BALB/c mice (n = 5 per group). *p < 0.05, compared by Student’s 
t test. Please see Supplemental Figure 4a for a schematic representation of this experiment. E. 
Frequency of donor (H-2Kd+Kb-) CD4+Foxp3+ Tregs in the WT>WT and WT>Cd40-KO 
BM chimeras reconstituted with lin- and Tregs (n = 5 per group). *p < 0.05, compared by 
Student’s t test. F. Cumulative data showing the MFI of Foxp3 on Treg cells. G. IL-17 
production by Foxp3lowTregs in Cd40-KO recipients (n = 5 per group). **p < 0.005, 
compared by Student’s t test. H. Representative gating strategy for Foxp3 and IL-17 analysis 
in the different BM chimeras. I. Quantitative RT-PCR analysis of Ox40l gene expression in 
WT and Cd40-KO BM-MSCs treated in vitro with IFN-γ , TNF, or their combination (n = 5 
per group). ****p < 0.0001, multiple comparisons using a one-way ANOVA. J. 
Representative images of OX40L staining in BM sections of the WT>WT and WT>Cd40-
KO BM chimeras. Mesenchymal-like elements (arrows) are shown in greater detail in 
Supplemental Fig. 4c. 
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Figure 4 Downregulation of CD40 expression in the BM-MSCs of aGVHD mice. A.  
Frequency of B220+ B-cells, CD4+Foxp3- Teffs releasing IFNγ and TNF, CD8+ T-cells 
releasing IFNγ and TNF and CD4+Foxp3+ Tregs in the aGVHD mice compared to control 
animals. *p < 0.05, **p < 0.005, ***p < 0.001, compared by Student’s t test. PB FACS 
analysis showing changes in the frequency of B. B-cells and C. Tregs at days 7, 14, and 21 
post-allogeneic BMT compared to controls (n = 5 per group). ***p < 0.001, compared by 
Student’s t test. D. qPCR analysis of Cd40 expression in BM-MSCs isolated from aGVHD 
and control mice. **p < 0.005, ***p < 0.001, compared by Student’s t test. E. Representative 
CD40 IHC staining in aGVHD mice (TD-BM B6 + Teff>BALB/c) compared to controls 
(TD-BM BALB/c + Teff>BALB/c). F. Representative co-immunofluorescence showing 
CD40 (green) and nestin (red) levels in aGVHD mice (TD-BM B6 + Teff>BALB/c) 
compared to controls (TD-BM BALB/c + Teff>BALB/c). G. Representative images of 
OX40L IHC staining in BM sections from allogeneic-transplanted animals (TD-BM + Teff 
B6>B/c) or controls (TD-BM BALB/c + Teff>BALB/c). H. Quantitative RT-PCR analysis of 
Ido1, and Nos2 expression in BM-MSCs isolated from allogeneic-transplanted animals (TD-
BM + Teff B6>B/c) and controls (TD-BM BALB/c + Teff>BALB/c).  
 
Figure 5 MHC-Ihigh MSCs are specifically eliminated in aGVHD mice. A. Frequency of 
MHChighCD40+, MHChighCD40- and of MHCnegCD40+ BM-MSCs in the Sca-1+ gate and B. 
Sca-1neg gate of Lin-CD44+CD29+ BM-MSCs in aGVHD vs controls mice. The analysis was 
performed at 14 days post-transplantation. *p < 0.05, **p < 0.005, ***p < 0.001, compared 
by Student’s t test, ****p < 0.0001, compared by Student’s t test. C. Representative gating 
strategy for the above analysis.  
  
Figure 6 OX40L expression is increased in the BM of aGVHD mice. A. Frequency of 
CD3, IFNγ+ and TNF+ Teff and B220+ cells in Cd40-KO and WT mice receiving an MHC-
mismatched BM. *p < 0.05, **p < 0.005, ***p < 0.001, compared by Student’s t test. B. 
Representative H&E and OX40L IHC images of BM sections from aGVHD (TD-BM + Teff 
B6>B/c) vs controls (TD-BM BALB/c + Teff>BALB/c) chimeras. 
 
Figure 7. Lack of CD40+ BM-MSCs in BOM from aGVHD patients. A. Representative 
double-marker immunofluorescence analysis for CD40 (red) and CD146 (green), showing 
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CD40 expression shared by CD146+ mesenchymal elements (red arrows) or confined to 
CD146- hematopoietic cells (white arrows). B. Pax5 IHC showing a variable expression of 
Pax5 with the highest fractions of Pax5+ cells observed in cases in which CD40 was 
expressed also in the mesenchymal cells. Patient’s characteristics and quantitative IHC data 
are included in Supplemental Table 1. 
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